Krassimir Mitchev

529 total citations
26 papers, 399 citations indexed

About

Krassimir Mitchev is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Krassimir Mitchev has authored 26 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 13 papers in Epidemiology and 11 papers in Immunology. Recurrent topics in Krassimir Mitchev's work include Inflammatory Bowel Disease (20 papers), Microscopic Colitis (13 papers) and Eosinophilic Esophagitis (7 papers). Krassimir Mitchev is often cited by papers focused on Inflammatory Bowel Disease (20 papers), Microscopic Colitis (13 papers) and Eosinophilic Esophagitis (7 papers). Krassimir Mitchev collaborates with scholars based in Belgium, France and Canada. Krassimir Mitchev's co-authors include Geert D’Haens, Séverine Vermeire, William J. Sandborn, Richard N. Fedorak, María T. Abreu, Jean–Frédéric Colombel, Paul Rutgeerts, Jean‐Louis Dupas, Pascal Dumortier and Marc Lémann and has published in prestigious journals such as Gastroenterology, Gut and The American Journal of Gastroenterology.

In The Last Decade

Krassimir Mitchev

24 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Krassimir Mitchev Belgium	8	316	260	116	79	36	26	399
D. Coscas Israel	8	325 1.0×	241 0.9×	80 0.7×	228 2.9×	21 0.6×	11	440
Jacqueline Jossen United States	10	263 0.8×	204 0.8×	86 0.7×	115 1.5×	11 0.3×	13	358
M. Ascolani Italy	10	234 0.7×	154 0.6×	126 1.1×	63 0.8×	21 0.6×	20	323
Takashi Shimoyama Japan	7	223 0.7×	144 0.6×	53 0.5×	179 2.3×	19 0.5×	10	356
Satoshi Motoya Japan	9	178 0.6×	126 0.5×	98 0.8×	69 0.9×	16 0.4×	12	272
Alexandra Thompson United Kingdom	6	150 0.5×	106 0.4×	94 0.8×	69 0.9×	60 1.7×	11	298
Gert A. Van Assche Belgium	8	290 0.9×	218 0.8×	84 0.7×	78 1.0×	12 0.3×	83	330
J. Languepin France	8	94 0.3×	76 0.3×	181 1.6×	52 0.7×	89 2.5×	25	358
Sarah Caspersen Denmark	4	281 0.9×	242 0.9×	68 0.6×	67 0.8×	11 0.3×	5	358
Lorena Rodríguez‐Alonso Spain	10	245 0.8×	237 0.9×	185 1.6×	62 0.8×	50 1.4×	27	421

Countries citing papers authored by Krassimir Mitchev

Since Specialization

Citations

This map shows the geographic impact of Krassimir Mitchev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krassimir Mitchev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krassimir Mitchev more than expected).

Fields of papers citing papers by Krassimir Mitchev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krassimir Mitchev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krassimir Mitchev. The network helps show where Krassimir Mitchev may publish in the future.

Co-authorship network of co-authors of Krassimir Mitchev

This figure shows the co-authorship network connecting the top 25 collaborators of Krassimir Mitchev. A scholar is included among the top collaborators of Krassimir Mitchev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krassimir Mitchev. Krassimir Mitchev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lafayette, Richard, et al.. (2025). #3337 The NefXtend trial, investigating extended nefecon treatment beyond 9 months in patients with IgAN. Nephrology Dialysis Transplantation. 40(Supplement_3).

Hébuterne, Xavier, Marc Lémann, Yoram Bouhnik, et al.. (2012). Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut. 62(2). 201–208. 129 indexed citations

Sandborn, William J., María T. Abreu, Geert D’Haens, et al.. (2010). Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab. Clinical Gastroenterology and Hepatology. 8(8). 688–695.e2. 119 indexed citations

Vermeire, Séverine, Stefanie Howaldt, Daan W. Hommes, et al.. (2010). Compassionate Use of Certolizumab Pegol in Patients with Crohnʼs Disease Who Have Failed Previous TNF Inhibitor Therapies. The American Journal of Gastroenterology. 105. S416–S416. 1 indexed citations

Hébuterne, Xavier, Marc Lémann, Jean‐Louis Dupas, et al.. (2010). Endoscopic Improvement in Patients with Active Crohnʼs Disease Treated with Certolizumab Pegol: Results of Blinded Central Reading of Recorded Endoscopies from the MUSIC Study (NCT00297648). The American Journal of Gastroenterology. 105. S418–S419. 4 indexed citations

Sandborn, William J., María T. Abreu, Geert D’Haens, et al.. (2010). S1030 Predictors of Response and Remission to Certolizumab Pegol in Patients With Crohn's Disease: Data From the WELCOME Study. Gastroenterology. 138(5). S–164. 6 indexed citations

Colombel, Jean–Frédéric, Marc Lémann, Yoram Bouhnik, et al.. (2010). S1045 Endoscopic Mucosal Improvement in Patients With Active Crohn's Disease Treated With Certolizumab Pegol: Week 10 and 54 Results of the Music Trial. Gastroenterology. 138(5). S–166. 13 indexed citations

Sandborn, William J., María T. Abreu, Geert D’Haens, et al.. (2009). Efficacy of certolizumab pegol in Crohnʼs disease patients with secondary failure to infliximab is not affected by concommittant medications. Inflammatory Bowel Diseases. 15. S15–S16. 1 indexed citations

Sandborn, William J., Séverine Vermeire, Geert D’Haens, et al.. (2009). Efficacy of certolizumab pegol is not affected by baseline anti-infliximab antibody status in patients with Crohnʼs disease with secondary infliximab failure. Inflammatory Bowel Diseases. 15. S13–S14. 1 indexed citations

10.

Sandborn, William J., Séverine Vermeire, Geert D’Haens, et al.. (2009). 143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab. Gastroenterology. 136(5). A–27. 8 indexed citations

11.

Colombel, Jean–Frédéric, et al.. (2009). S1065 Predictors of Endoscopic Response and Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Logistic Regression Analysis of the Music Data. Gastroenterology. 136(5). A–181. 2 indexed citations

12.

Sandborn, William J., Séverine Vermeire, María T. Abreu, et al.. (2009). Efficacy of Certolizumab Pegol in Crohnʼs Disease Patients with Secondary Failure to Infliximab Is Not Affected by Concomitant Medications. The American Journal of Gastroenterology. 104. S451–S452. 1 indexed citations

13.

Vermeire, Séverine, María T. Abreu, Geert D’Haens, et al.. (2008). 494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study. Gastroenterology. 134(4). A–67. 18 indexed citations

14.

Vermeire, Séverine, María T. Abreu, G D’Haens, et al.. (2008). 9 ASSESSMENT OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF CROHN'S DISEASE IN PATIENTS FOR WHOM INFLIXIMAB TREATMENT WAS NOT SUCCESSFUL: OPEN-LABEL INDUCTION PRELIMINARY RESULTS FROM THE WELCOME STUDY. 2(1). 4–4. 1 indexed citations

15.

Vos, Christine De, et al.. (2008). Non-Interventional Study Comparing Treatment Satisfaction in Patients Treated with Antihistamines. Clinical Drug Investigation. 28(4). 221–230. 23 indexed citations

16.

Vermeire, Séverine, María T. Abreu, Geert D’Haens, et al.. (2008). Efficacy and Safety of Certolizumab Pegol in patients with active Crohnʼs Disease who previously lost response or were intolerant to Infliximab: Open-Label induction results of the WELCOME Study. Inflammatory Bowel Diseases. 14. S30–S30. 2 indexed citations

17.

Colombel, J.F., Marc Lémann, Olivier Dewit, et al.. (2008). Endoscopic Mucosal improvement in patients with active Crohnʼs Disease treated with Certolizumab Pegol: First results of the MUSIC Clinical Trial. Inflammatory Bowel Diseases. 14. S25–S25. 2 indexed citations

18.

Colombel, J F, Marc Lémann, Olivier Dewit, et al.. (2008). Endoscopic Mucosal improvement in patients with active Crohnʼs Disease treated with Certolizumab Pegol. Inflammatory Bowel Diseases. 14. S25–S25. 19 indexed citations

19.

Vermeire, Séverine, et al.. (2008). Certolizumab pegol in patients with Crohnʼs disease who failed treatment with other anti-TNFs: data from a compassionate use program. Inflammatory Bowel Diseases. 14. S29–S29. 3 indexed citations

20.

Mitchev, Krassimir, Pascal Dumortier, & Paul De Vuyst. (2002). `Black Spots' and Hyaline Pleural Plaques on the Parietal Pleura of 150 Urban Necropsy Cases. The American Journal of Surgical Pathology. 26(9). 1198–1206. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact